Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
A takeover wouldn't be unwelcome, and maybe a front runner could be Mylan/Upjohn (or now called Viatris). Mylan have been looking to buy up generic companies in the Asia/Pacific/Emerging markets territories. Looks like they may not be done according the write up below.
https://www.fiercepharma.com/pharma/mylan-sees-opportunity-for-m-a-after-upjohn-deal-exec
Sandoz (Novartis) have announced this week they're buying the Japanese arm of Aspen for Euro 300M - - so M&A's happening in this sector. That said I just found an old post I put on the ii site (July 2014) where I though BXP would be good for a takeover, so I'm not going to hold my breath this time :)
If we continue at this rate winnings1 we could be one of the highest paying dividend stocks on the LSE, and certainly in the healthcare sector. Q1 results out very soon but hopefully on track for a c8p EPS. With the 30% of profits having to be paid to shareholders, from next year, that would yield 5.7% on todays SP (GSK I think is the highest in healthcare at c4.67%)).
that should read "proposed" dividend..
Also paying a 1.4p dividend (-20% withholding tax) if you're still on the books in a fortnights time..
I'm not sure if this is still under the radar - quite a few sites not mentioning BXP in this weeks financial diary. Might also help to have new broker forecast at some point. Last one I could see was July 18 from Northland Capital @84p, and the results today have far exceeded their forecasts back then..
I've bought through ii but quite a few brokers allowing you to buy the AIM listed GDRs..
Lets hope today's release of final year results puts BXP on the radar..
With a NAV at 72.99 tk (67p), hopefully we can start moving closer to this now on AIM, and then beyond. I calculated the EPS to be 1.95 tk for Q4, so up from the 1.84 reported in Q3 (+ above the other quarters).
that should have read "by" the 11th of November (as per RNS)..
Good to see some movement today. Worth noting that when the prelim results were released last year (26th of Oct 18) there wasn't much SP movement. This didn't really happen until the full 12 month results were released (7th of November). We'll be receiving the full accounts on the 11th of Nov this year, so hopefully that's when we'll see a greater rise.
We could see a "Notification of Preliminary Results and Annual General Meeting" RNS tomorrow, or later this week. This will inform us of the proposed dividend, as well as the EPS and NAV calculations.
Would have been nice to have more detail on why their Phase 3 study failed. It would allow us to make our own judgement on whether it's likely to happen again. I'm still surprised at the P3 results , especially as HAL Allergy BV conducted an almost identical trial with highly statistically significant results. SC should have been at the very least equal in efficacy to SL.
Good post cyberduck - and nice to have a sanity check from someone else who's looked at the numbers..
The shortage of generics in the UK, and EU, has been hitting the news recently (link below). Partly due to the difficulty of some western companies competing on price with India and Bangladesh. Maybe more opportunity for BXP to help fill the gaps?
https://www.bbc.co.uk/news/health-49907056
Just to add I looked at BXPs last EU GMP inspection/certificate (available online - inspected this year). They passed, with no issues highlighted i.e. they can still manufacture for the EU/UK. No reason they should have failed but was worth double checking as still can't find any good reason for the recent drop in SP..
Take the dollar price - divide by 5 and apply the exchange rate - so would be $1.79/5/1.23 = 29p
US = 5 ordinary shares on AIM - current exchange $1.23 to the pound
It will be interesting to see how Corbyn plans to undercut a Bangladesh generics house when the average wage in Bangladesh is <£6k a year, and the biggest operating expense will be the workforce… Would be better striking a deal with BXP and get them to do the manufacturing instead! He just needs to put in a government run supply chain, QP, QPPV, regulatory team etc.. – can’t really see it myself!…
Not long to wait now for end of year results (7th Nov), or announcement of the dividend - probably end of Oct..
May be of some interest but link below to last years dividend..
https://www.adrbnymellon.com/publicSiteProxyExport.jsp?resourceName=getExportDsf&statusCode=F&cactnId=170000046931&exportFormat=pdf
With the dollar strengthening to the pound, the 1.49 cents dividend per share is worth a little more in today's money. We'll be looking at an EPS of c7p in the final results (PE ratio of c6). If 30% has to be distributed by law to shareholders - c2p per share should give a ~5% dividend yield on today's SP (although some of the dividend will no doubt be in shares)..
As a correction to a previous a post 1 GDR = 1 share on the Dhaka, they're the same. So as I understand it we actually receive a better dividend yield on AIM, given the GDR is significantly cheaper, but the dividend will be the same (like I say that's my understanding at least)..
I started looking at STX in 2016 when their SP was in the 180s… although there was potential there wasn’t too much to justify the SP at that time (IMHO at least)… Since then they’ve achieved a broad EU label, an EU licensing deal, positive H2H study, and now a US label with a broader indication than we expected in 2016. I was lucky enough to buy in at 16p and top up in the 20s and 30s (when they broadened their EU label + had encouraging signals from the FDA). Normally I’d be exiting at this level of return but seeing what STX have now, and comparing to what they had in 2016 (where the SP hit 188p), I’m confident we have a fair bit to go, so holding for the time being ..
I'm not sure if anyone else looks at this BB but welcome thoughts on today's RNS (pasted below). I assume this law is to encourage investment in Bangladesh companies? - not sure therefore why the SPs not responding positively. The company can still pay down debt, expand, and could pay 15% cash dividend + 15% stock as I see it. As as shareholder it seems quite positive and was anticipating a 15% cash dividend this year anyway. Be great to hear other thoughts though..
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No. : 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that new legislation in Bangladesh, which has been introduced by the new Finance Act with effect from 1 July 2019, will affect the Company's dividend policy with respect to future dividend declarations.
The Bangladesh Government has introduced a law which, in effect, means that all listed companies will have to pay at least 30 percent of their net after-tax profit of any income year as dividends to their shareholders or face an additional tax charge of 10 percent on the total amount of earning retained in that income year. Dividends may be paid in cash or stock, however, the law provides that if the stock dividend exceeds the cash dividend, an additional 10 percent tax shall be chargeable on the amount of stock dividend declared.
The Company will review the legislation in detail and consider how to best manage the cash flow to deliver long-term shareholder value. The Company policy will be decided in due course.
Just to make a clarification on my previous post - it was 1.25 BDT we received per GDR last year. This equated to the 1.49 cents showing on my statement, and the 1.15p that shows on this site under dividend. 20% tax was taken at source.
Be nice to get a trading update on full year results (to end of June 19) but this doesn't normally get released till Nov.. None the less it should be very good... We might hear about the dividend earlier though.
looks like the "summer sale" on AIM is over?